Matching placebo to omarigliptin

DRUG3 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Type 2 Diabetes Mellitus

Phase 3

Omarigliptin (MK-3102) Clinical Trial - Add-on to Oral Antihyperglycemic Agent Study in Japanese Participants With Type 2 Diabetes Mellitus (MK-3102-015)

CompletedNCT01697592

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2012-10-24End: 2014-05-08Updated: 2018-09-10

Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)

CompletedNCT01704261

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2012-10-18End: 2014-12-23Updated: 2018-09-10

A Study to Evaluate the Safety, Tolerability, and Efficacy of the Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy (MK-3102-024)

CompletedNCT01755156

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-01-11End: 2016-03-16Updated: 2018-09-10

Related Papers

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

BMC Endocrine Disorders2017-11-0611 citations

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadequate Glycemic Control.

2017-06-066 citations